Team

There’s a lot to each of us. And we bring it all together – as one.

Our Partners are recognised business leaders. They have each founded and built companies, gained a wealth of investment and M&A expertise, and serve on many prominent boards.
Our Investment Team has helped create 5 Nasdaq and 3 ASX listed companies, and realised returns to investors of over $1 billion.

That’s how, together, we have a proven track record of picking and building winning investment opportunities.

View Careers Opportunities


Dr Michelle Deaker

Founding Partner & Managing Director
Close

Dr Michelle Deaker

Founding Partner & Managing Director
  • Education

    BSc(Hons), MSc, PhD

Dr Michelle Deaker is a Founding Partner & Managing Director of OneVentures and has been primarily responsible for the foundation of OneVentures firm and capital raisings of OneVentures Funds. The firm now has over $550M in funds under management. Michelle serves on the investment committee of OneVentures three main Funds, leads the technology practice within the firm and is responsible for investor relations managing the supervisory boards of OneVentures funds.

Michelle has over 20 years experience in the development of high growth technology companies in Australia and the US, has served on the boards of large and small listed and unlisted companies and has a strong background in Australian R&D and expertise in global business expansion. She has negotiated technology transfer contracts with research institutions; established financing syndicates with Australian, Asian and US investors; chaired the boards of several high growth companies; supported early breakthrough commercial contracts; leveraged her extensive networks for the benefit of OneVentures companies; and negotiated both financing and exit transactions.

Michelle established OneVentures in late 2006, coming into the venture capital industry as a successful IT industry business owner, entrepreneur and subsequently angel investor. The Company she founded in 1999, E Com Industries (www.giftvouchers.com), became the leading prepaid card and electronic voucher provider in Australia, servicing over 100 major retail brands including Coles Myer and Woolworths, managing $700m in Australian retail liability and eventually expanding operations into the United Kingdom, South Africa and New Zealand. E Com was acquired by UK publicly listed company, Retail Decisions, in 2005, in a transaction returning to investors 4.6xcapital and an average IRR of 70%. Notably, E Com industries was one of only a handful of Australian companies that successfully migrated the dotcom boom and crash through to a successful outcome for investors. Prior to E Com Industries, Michelle established IT enterprise business, Networks Beyond 2000.

Michelle holds a Bachelor of Science (Honours 1st class), Master of Science and a PhD (Applied Science). She is a member of the Australian Institute of Company Directors and Chief Executive Women (CEW).

Portfolio Board Roles
In the news
Ventures

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec mattis id erat eu molestie. Integer in facilisis neque, sit amet maximus leo. Maecenas vehicula volutpat risus, sed tempor massa laoreet egestas. Sed tincidunt imperdiet augue quis aliquet. Suspendisse id purus commodo, pharetra sapien id, egestas urna. Sed ornare diam sit amet sem dapibus bibendum. Vestibulum facilisis auctor cursus.

Dr Paul Kelly

Founding Partner
Close

Dr Paul Kelly

Founding Partner

Dr Paul Kelly is Founding Partner at OneVentures. Starting with his background as an Australian Physician, Paul has a long history of biotechnology entrepreneurship and healthcare investing, from developing innovation to commercialising at scale and realising substantial returns for investors.

Having returned to Australia in 2010 (after 15 years in the UK and US), he is dedicated to improving healthcare and treatment options for populations across the world. He lives and invests guided by his vision for a better future: through innovation, collaboration, and patient determination.

Paul is an avid reader and can regularly be found immersed in medical journals as well as fiction and non-fiction literature, which he believes “provides perspectives and insights that you would never get from management or business books”.

When he’s not mentoring and encouraging medical professionals to be entrepreneurial, he also looks after the health of our native environment: being highly active in bush regeneration and preservation.

Paul serves on the investment committees of OneVentures’ four main Funds, chairing the Fund III Investment Committee, and leading the healthcare and biotechnology practice across the firm.

Paul is a highly experienced executive and has multiple board responsibilities as either Chair or as a Non-Executive Director within numerous OneVentures portfolio companies. Independently of OneVentures, he is also a Non-Executive Director Garvan Institute of Medical Research

Paul has over 30 years’ experience in developing and commercialising biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, delivering strong returns for shareholders and investors as a founder and CEO.

Notably, Paul served as Co-Founder and CEO of Gemini Genomics (Nasdaq:GMNI), one of the world’s first clinical genomics companies, commercialising novel gene-based diagnostic and therapeutic targets. At Gemini, Paul led the company in one of the UK’s largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world’s leading research institutions and biotechnology and pharmaceutical companies. In 2001, Paul led the company’s successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over US$250M.

Paul’s other notable achievements include co-founding Agamatrix, now a leading bio-sensing medical device company with operations across the US and South East Asia, and Atomera (Nasdaq ATMR). He then served as President and CEO of Orchid Cellmark (Nasdaq:ORCH) – during his tenure revenues grew by over 50% in 2 years to $60M per annum, and increased the company valuation 10 fold.

While in the US Paul also served as President and CEO of Medcenter Solutions, a US based online medical education and pharmaceutical marketing company.

Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specialising in endocrinology at St Vincent’s Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute of Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.

Paul has also served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. He also serves on the UNSW Medicine Dean’s Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.

Portfolio Board Roles
In the news

Nick Gainsley

Partner
Close

Nick Gainsley

Partner
  • Education

    BSc(Hons), AMCT

  • 1V PortCo Board Roles

    Edrolo (Board observer) | Hivery (Board observer)

Nick Gainsley is a Partner at OneVentures and leads the Venture Credit practice of the firm. Nick is committed to ensuring that companies in Australia can access alternative forms of capital by bringing his extensive global experience with debt and financing to the local market.

As one of the leading pioneers of Venture Credit in Australia, Nick is in high demand as a keynote speaker and conference panellist. He regularly appears in the media as an expert on Venture Credit and alternative debt financing. For media and speaking enquiries, please contact us.

Nick is a keen skier and loves to travel the world – with his young family in tow. Being a Brit he used to long haul and is looking forward to the direct Sydney-London flight in the coming years. He loves to ski steep off-piste terrain however he’s been forced to recalibrate to “family friendly” black runs.

Nick brings over 15 years of debt experience both in direct lending and advisory, in Europe and Australia. He has nearly 10 years of venture credit experience having led investments to over 100 high growth technology companies across 11 countries.

At OneVentures, he serves on the Investment Committee of the 1V Venture Credit Fund IV and the OneVentures Growth Fund V.

Prior to joining OneVentures in May 2019, Nick was based in the UK and was a Principal at Kreos Capital, Europe’s largest growth debt fund. His experience there covered deal origination, execution and portfolio management for a significant number of transactions across European markets. He has wider sector experience across technology sub-sectors including FinTech, software, cyber security, hardware, e-commerce/DTC, AdTech and life science, investing in both private and public companies.

Prior to this Nick was a Manager at KPMG in London within its Debt Advisory team, where he was involved in managing and advising on a range of debt transactions from mid-market to large cap. Transaction experience covered leveraged finance, corporate refinancing, capital market issuance and strategic financing advice.

Nick is currently a mentor at Stone & Chalk, and an advisory board member at Cloudfloat

Portfolio Board Roles

Anne-Marie Birkill

Co-Founder, Venture Partner and Director
Close

Anne-Marie Birkill

Co-Founder, Venture Partner and Director
  • Education

    BSc(Hons), MBA, GAICD

Anne-Marie Birkill is a Co-Founder, Venture Partner, and Director of the Manager at OneVentures. She is well regarded for her passion for and experience of working with early-stage technology companies and entrepreneurs including as an expert advisor within the innovation community. She is based in Brisbane, a strong source of technology innovation opportunities.

Driven by a passion to grow Australia’s knowledge-based economy; Anne-Marie brings 35+ years’ experience in executive leadership, product development and commercialisation, advisory roles, mentorship, capital raising and exits to the team at OneVentures. Her expertise in spans both the technology and healthcare sectors.

A committed advocate for diversity, equity and inclusion, Anne-Marie regularly contributes to thought leadership on this topic including via speaking engagements. For media and speaking enquiries, please contact us)

Anne-Marie prioritises kindness in all she does and has a natural curiosity traversing many interests. Whether hiking remote trails, planning her latest renovation project; or cooking up a storm for family and friends, she really does nothing by halves.

Anne-Marie lives in vivid colour and is the most likely team member in the office to protest about any promotional materials being printed in grey.

Anne-Marie serves on the investment committees of OneVentures’ Funds I, II and III and the REM and Risk Management Committees.

Anne-Marie is a highly experienced executive and has board responsibilities as a Director within OneVentures portfolio companies iStaySafe and Madorra.

Anne-Marie’s interest in the innovation sector was forged during 15 years in leadership roles in agri-business companies developing and commercialising new cultivars of ornamental, aquatic, food, and forestry plants. Prior to co-founding OneVentures in 2010, she was CEO of i.lab Incubator, having previously spent five years in the senior management team at UniQuest. During this period Anne-Marie developed successful programs and networks to assist technology commercialisation, start-up formation and growth, capital raising and exit. She has experience of senior management in listed and unlisted companies and was a Director for energy storage company RedFlow Limited during its successful listing on the ASX (ASX:RFX).

Anne-Marie was Chair of the Board of Charm Health until 2017 when she lead the company to an acquisition by the Citadel Group (ASX:CGL). She originated Vaxxas in 2010 and was an observer to the Vaxxas Board until 2020.

Her experience and reputation in the technology sector is demonstrated through her active participation in the innovation community. She is currently an Industry Fellow with The University of Queensland (UQ) Business School, a director for InterFinancial Corporate Finance and a member of the Advisory Panel for the $100M Advance Queensland Business Investment Fund. She is an inaugural member of the AIC Champions of Change.

Portfolio Board Roles
In the news

Nigel Dews

Operating Partner
Close

Nigel Dews

Operating Partner
  • Education

    BEc (Hons), MBA

  • 1V PortCo Board Roles

    Lumary | Kepler Analytics (Chair) | Flippa | SourseAI

Nigel Dews is an Operating Partner at OneVentures and leads the Technology team within the firm. Nigel is a digital revolutionary, having been an Executive Leader in the digital media, technology and telecommunications industries for 20+ years.

Nigel is renowned for his experience as both a strategic consultant and a proven entrepreneur. He has experience as a start-up CEO as well as a strong history within large multinationals: providing critical leadership to pivot into the digital landscape.

Nigel was born in NZ, grew up in Australia and has also lived across both the US and Europe. Wherever he is in the world though, he loves the outdoors – with a bias towards Central Otago. Whether he’s hiking, running or catching a wave with his family, Nigel rarely stops moving when he’s out of the office.

Nigel joined OneVentures to predominantly to work with our digital and technology-based portfolio businesses. He currently serves on the Investment Committee of the OneVentures Growth Fund V, advises the Fund IV team and works extensively with our portfolio companies.

Nigel is a highly experienced executive, consultant and has board responsibilities as a Director with OneVentures portfolio companies Lumary, Kepler Analytics, Flippa and SourseAI.

Nigel has been a leader in the digital media, technology and telecommunications industries as CEO of Vodafone Hutchison Australia, 3 Mobile, and the first Chief Executive of the Fairfax Media digital business. More recently, Nigel was CEO of Melbourne-based technology scale-up, Message Media, leading the strategy development and execution to rapidly grow via organic sales acceleration, acquisitions, new products and geographic expansion, attracting private equity and leading to an eventual trade sale.

Nigel initially worked at the Reserve Bank of Australia, spent five years in strategy consulting with McKinsey & Company before moving into leadership positions in the emerging category of digital media.

He built and led the start-up of Fairfax Digital for its first seven years, taking it through to break-even. He led the building of a diverse portfolio of organically grown, joint ventured and acquired digital businesses.

Nigel has held notable leadership roles including CEO of Hutchison Telecoms Australia (HTA) and 3 Mobile, leading the merger and integration of 3 with Vodafone, remaining as CEO of the merged entity for its first 3 years.

After starting-up European border mobile network enabler Hue in the UK, Nigel returned to Sydney and joined strategy consultants Port Jackson Partners as a Director and shareholder leading strategy projects across a range of industries in Australia, New Zealand, United Arab Emirates and United Kingdom. This included work with CEOs of fast growing digital businesses, digital and technology strategies, media, infrastructure, agriculture and international growth initiatives.

Nigel joined Message Media in 2017 to scale-up and transform the business from a single region, single product, single shareholder business via a substantial investment in technology, people, new processes and platforms, and acquisitions, culminating in a significant private equity investment and founder exit. He is also a founding partner of GNG Partners, a boutique growth strategy consulting firm.

Portfolio Board Roles

Dr Dan Baker

Venture Partner
Close

Dr Dan Baker

Venture Partner
  • Education

    BSc (Biology), MD (Rheumatology)

Dan Baker received his B.A. in Biology from Gettysburg College and his medical degree from the University of Pennsylvania. He completed his medical residency at Hershey Medical Center and fellowship in Rheumatology at the University of Pennsylvania, followed by a research fellowship in Rheumatology at Mass General Hospital. He continued on the faculty of the University of Pennsylvania for 18 years before joining Janssen/Centocor in 2000.

As Vice President Immunology R&D at Janssen, his responsibilities included the clinical development of Remicade, SIMPONI and STELARA as well as other programs in rheumatology, and dermatology. As Disease Area Stronghold Leader he was responsible for Phase II & III clinical development plans for rheumatology products was responsible for the overall strategy on portfolio in rheumatology/immunology.

He has authored multiple publications in the field of immunology and has served a co-Lead of RTCure which is an academic/industry collaboration that is sponsored by IMI2 and is searching for tolerogenic therapies for rheumatoid arthritis.

After his retirement from Janssen in 2019 he has been active in continuing to be involved in bringing therapies to patients by providing scientific advice to drug development organisations. He has taken on the role of CEO of Kira Biotech which is an emerging Australian biotech company targeting treatment of immune system disorders with novel immunomodulatory drugs

Kelly Constable

Venture Partner
Close

Kelly Constable

Venture Partner
  • Education

    Ba Speech Communication

Kelly Constable is a senior business executive offering 20 years of international commercialisation expertise in life sciences. Kelly’s expertise includes eight years leading breakthrough digital applications in precision medicine in the US and EU. She has a proven track record driving value in a top global biotech organization, through partnerships with multinational corporations and as a strategic thinker on startup Boards and teams.

Currently, Kelly is the Co-Founder and CEO of AULUS Partners, dedicated to accelerating commercialisation of high potential life sciences and med tech companies. She is the Chief Strategy Officer for Omico, a precision oncology clinical trials platform. She joined OneVentures Healthcare Fund as a part-time Venture Partner to focus on internationalising existing portfolio companies and to identify new opportunities. She serves on the Board of Directors of Prota Therapeutics, Oculo, and ANDHealth. Kelly serves as an expert advisor and commercial lead to NSW Health Gene Therapy and Manufacturing Initiative and she serves on the Investment Committee of the NSW Medical Device Fund.

Kelly developed her expertise at Abbott Labs through various roles in sales and marketing across general medicine and specialty therapeutics. Kelly joined Amgen in 2006, a world leader in biotechnology. She led the launch of the Sureclick autoinjector in 2006 and repositioned Aranesp after a FDA label change and led the US launch strategy for Prolia in osteoporosis in 2009, each >$1B annual sales products. More recently, Kelly led the global launch strategy for Aimovig in migraine through 2016.

Kelly developed her expertise in digital health and precision medicine when she was asked by Amgen to create a dedicated US innovation unit. In this role, she led and negotiated Amgen’s first technical alliance with GE Healthcare and through this strategic partnership, developed and launched the first  point of care software algorithm in osteoporosis, deployed initially in the US and now globally. Next Kelly co-founded Amgen’s first precision oncology initiative as a start-up inside Amgen, developing a  novel algorithm for anaemia in cancer, raising $20M of seed funding and managing Amgen’s first commercial software team with 50 cross-discipline experts in mathematics, software, biotech, regulatory, operations, and commercialisation. She oversaw the development and implementation of Amgen’s first software medical device solution in Germany which has since been launched in multiple countries across Europe. Kelly also served as the expert advisor in digital health to Amgen Ventures, the company’s Corporate Venture Fund, reviewing opportunities and participating in funding transactions.

In 2016, Kelly left corporate life after 20 years to become a full-time entrepreneur. She founded AULUS Partners with a mission to embrace start-ups that harness the potential to transform healthcare issues on a global scale. Currently AULUS is associated with four portfolio companies in the USA.

John Westwater

Venture Partner
Close

John Westwater

Venture Partner
  • Education

    BSc(Hons), PhD

John brings almost 20 years’ global life science experience across operational, venture capital and investment banking roles.

Most recently John held the role of CFO at Elastagen, an innovative Australian medical device company, until it was sold to Allergan, a global medical aesthetics company. The deal was recognised by the AIC as the Best Venture Capital Investment of 2018. Post-closing, John continued to oversee the integration of Elastagen’s clinical programs at Allergan as Director R&D, and latterly as a consultant.

During his tenure at Elastagen and Allergan, John had a broad remit that spanned finance, corporate development and clinical functions, and was intimately involved in internationalizing the business through to its successful exit. As CFO, John led the Company’s fund-raising efforts including the Series B round. He was also heavily involved in the design and execution of the Company’s two clinical studies conducted in the UK.

Prior to Elastagen, Dr Westwater spent eight years at Nomura Phase4 Ventures in London, investing in early to mid-stage life sciences companies primarily in the US and Europe. John started his career in investment banking with Morgan Stanley where he spent over four years in their Corporate Finance and Mergers, Acquisitions and Restructuring Department (MARD) teams, advising pre-IPO to blue-chip healthcare multinationals on various capital raisings, divestitures and acquisitions.

At different times in his career, John has also been an independent healthcare consultant, providing strategic advice to various companies through the years.

Dr Westwater holds a PhD and a BSc (Hons) in Biochemistry from Heriot Watt University in the UK with the first year of his PhD studies spent at Dundee University. He is also a recipient of the Watt Club Medal.

Sarah Meibusch

Partner
Close

Sarah Meibusch

Partner
  • Education

    BAgrSc(Hons), M.P.S, GAICD

  • Location

    Brisbane, AU

Sarah is responsible for sourcing life sciences companies and actively shaping their future. She applies her global executional experience and entrepreneurial passion to nurture their success. Her enterprise level leadership experience has been forged over 20 years in a wide spectrum of organisations, including start-up, private companies, ASX and NASDAQ-listed companies, a multi-national pharmaceutical company and university research organisations.

Prior to OneVentures, she was the Asian Business Development lead for Shire Pharmaceuticals (now Takeda), a global specialty pharmaceutical company. Sarah identified technologies and developed collaborations across Japan, Korea, Australia, New Zealand, Singapore and Taiwan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015.

Sarah has held senior management roles at Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics. From 2011-2017 she led the development of the new UQ QAAFI research institute from 32 people to 450 people and a financially profitable position within 5 years. This included leading the negotiation of a complex $70+M staff transfer and research agreement for QAAFI between the University of Queensland and the Queensland Government. In 2012, Sarah spearheaded the IP asset assignment and company wind-up of 20 year $168M Beef Co-operative Research Centre, involving five universities across five state jurisdictions, MLA, CSIRO and Meat and Lamb NZ and pastoral companies. At Progen Pharmaceuticals, Sarah worked collaboratively with the CEO and CFO over several years to secure a total financing of ~$125M via five capital raisings for oncology drug development, and in 2008 led the $22M acquisition of an oncology drug discovery company.

Sarah has a strong understanding of the pharmaceutical, medical device and healthcare industries including key inflexion points, intellectual property, regulatory and reimbursement strategies, business development options and strategic product management. She combines this with the ability to understand scientific information quickly and build credibility with technical experts and industry players. She is passionate about commercialising new technologies, and has the strategic vision and positive energy to deliver under tight timeframes in a team environment.

Sarah is a graduate of the Australian Institute of Company Directors (GAICD) and currently holds directorships with Kira Biotech, QAAFI Advisory Board and Life Sciences Queensland. She holds Bachelor level science qualifications from the University of Queensland and a Masters from Cornell University and has completed a postgraduate course at Harvard Business School focusing on negotiation and decision making.

Dr Jeannie Joughin

Principal
Close

Dr Jeannie Joughin

Principal
  • Education

    BSc (Hons), PhD

  • Location

    Melbourne, AU

  • Current board roles

    Paranta Biosciences

  • Previous

    Glutagen

Jeannie is an experienced biopharmaceutical and medical device leader with 20+ years’ experience locally and internationally. She is responsible for sourcing and supporting biotech, device and diagnostics companies to achieve future success. Having held senior executive level positions globally, she brings extensive expertise in business development transactions, strategic partnerships and alliance management to support investment strategy. Her operational and leadership experience in research, clinical trial and commercial management has been forged through conducting research at universities, holding positions of increasing seniority in multi-national pharmaceutical companies and from start-up environments in private and listed companies located in the USA, Europe and Australia.

Prior to OneVentures, Jeannie held senior executive and advisor positions in Australia and currently serves as a director for Paranta Biosciences. While in the US she was responsible for global business development activities and successfully licensed a medical device technology to several of the world’s largest pharmaceutical companies attracting sizable milestone and royalty payments. She has demonstrated commercial success and operational expertise by building businesses and brands in several therapeutic areas in different geographies. She has a global perspective with strong analytical, regulatory and technical skills, and is passionate about working with and developing teams to support execution of corporate, product and business strategy. This experience has come from working in companies in Australia and the USA including Bristol-Myers Squibb, Mayne Pharma, CSL and CSL Behring, Enable Injections Inc., Paradigm Biopharmaceuticals, Glutagen and Paranta Biosciences.

Dr Joughin holds a PhD and a Bachelor of Science (Hons) in Immunology from Monash University in Melbourne and a Diploma of Marketing from the Melbourne Business School.

Kate Madden

Investment Manager
Close

Kate Madden

Investment Manager
  • Education

    CA, BBA (Hons)

Kate joins OneVentures from Ireland, before moving to Australia she qualified as a Chartered Accountant with PwC, Dublin. She worked in the Deals department in Business Restructuring Services and spent some time at KKR, working within their private credit arm.

Kate has a Bachelor of Business Studies degree with a major in Accounting and Finance from the University of Limerick and is a member of the Institute of Chartered Accountants Ireland and the Irish Australian Chamber of Commerce. She loves to travel and cook.

 

Bernard Chin

Head of Fund Finance
Close

Bernard Chin

Head of Fund Finance
  • Education

    CA, BaCom (Accounting and Finance)

Bernard has experience in the private equity, investment banking and audit professional services industry. He started his career at KPMG in Sydney where he initially qualified as a Chartered Accountant.

He then spent several years working for Catalyst Investment, a private equity manager in Sydney, before moving to London and working for the UK based private equity firm BC Partners.

Upon returning to Sydney he spent some time at Macquarie Investment Management in a financial control function.

Bernard has a Bachelor of Commerce degree from the University of New South Wales and is a member of the Institute of Chartered Accountants in Australia and New Zealand.

Maria Baas

Investment Relations Director
Close

Maria Baas

Investment Relations Director
  • Education

    BA

  • Location

    Sydney, AU

Maria Baas is the Investment Relations Manager at OneVentures. She is responsible for developing, managing investor relationships and implementing Investor Relations strategy and helping to build out the firm’s Investor Relations capability in the Australian market.

Maria joined the team from Macquarie Group where she was developing strategic relationships with external stakeholders in the Corporate and Asset Finance division. Prior to that Maria worked at UBS Asset Management where she was responsible for key client relationship management and institutional business development across industry super funds, insurance firms, large corporates and consultants. Maria also held various roles in financial planning and funds management with AMP Capital and AMP Limited more broadly. She started her career in HNW boutique wealth management firm as the Client Relationship Manager.

Maria holds a Bachelors Degree in HR and Industrial Relations from the University of Sydney. Additionally, she has completed a Graduate Certificate of Finance at Macquarie University and a Diploma of Financial Planning.

Carolyn Miller

Head of Marketing and Communications
Close

Carolyn Miller

Head of Marketing and Communications
  • Education

    eMBA / GAICD

Carolyn is a highly experienced marketer who is passionate about investing and the promotion of innovative companies.

With over 20+ years of experience in marketing, she’s also a regular panellist on the highly popular ABC Television Program ‘Gruen’, where industry experts review and discuss marketing creative concepts and strategies.

Carolyn founded her own communications consultancy The Honeycomb Effect, and has had extensive experience across a broad range of clients. Prior to this she also worked as a strategist at a variety of award winning agencies, as well as being promoted to Head of Vertuo during her tenure at Nespresso.

Carolyn is an engaging storyteller who loves public speaking and is regularly in demand as a marketing expert for conferences and events. She’s also much taller in real life than what she appears on the telly (so she’s been told… at 6’2”+ heels).

Carolyn brings her entrepreneurial spirit to the OneVentures team, delivering the strategic marketing plan and ensuring timely execution. She is responsible for communications, PR, social media, digital and events.

Carolyn is passionate about Women’s health and was a Non-Executive Director of the Board at Family Planning NSW from 2012 to 2018. She was elected as Vice President in 2015, working with the Executive Leadership team to ensure women from all backgrounds have access to reliable and affordable healthcare services, particularly in area of reproductive health.

Carolyn also serves as a Non-Executive Director on the Board of Tourism Tasmania, and is committed to the ecological development of tourism in the apple isle.

Prior to joining OneVentures she had already taken an interest in private equity investing, focused on bio-tech innovation and emerging asset classes.

Justine Carzino

Investment Director
Close

Justine Carzino

Investment Director
  • Education

    BCom / CA

Justine is a highly regarded Investment Director at OneVentures and is responsible for the new Victorian Growth Fund, focusing on providing Venture Credit to Victoria’s most exciting start ups.

She brings her wealth of knowledge in M&A Advisory, her passion for entrepreurship and her experience with capital raising to the Venture Credit team. She is a valued advisor and is driving the awareness and adoption of Venture Credit (also known as venture Debt) in the Australian market.

Justine returned to Australia in late 2021, after 3 years working in Tokyo advising life science and beauty companies on cross border M&A. During her time in Tokyo, she also published a number of articles on M&A trends within the beauty and personal care sector and successfully completed Level I and II of the CFA program.

Justine leads the investment team for the Victorian Growth Fund. She is responsible for identifying and assessing potential investments, promoting the Fund and managing the partnership with the Victorian Government and other stakeholders.

Prior to joining OneVentures, Justine advanced her career at Deloitte working with high growth companies and family offices on accounting and tax compliance, structuring and advisory. During her tenure, she helped to drive Victorian representation in Deloitte’s annual Tech Fast 50 awards.

She continued to work with founders and investors in M&A Advisory where she spent many years advising on buy side, sell side transactions and capital raises, with a focus on healthcare services and consumer business.

Justine is passionate about innovation in Victoria, and takes great pride in being able to fund companies in order to see their products and services commercialised and brought to market.

Jim Scopa

Close

Jim Scopa

Walter Lewin

Chairman, Board of Directors
Close

Walter Lewin

Chairman, Board of Directors

Mr Lewin is Chair of the Board and Investment Committee for OneVentures Pty Ltd. He is a member of the Advisory Board of VGI Partners, a leading global investment firm based in Sydney and New York. Mr Lewin was a founding shareholding and Chair of the Advisory Board of OneVue (ASX: OVH) and was a founding shareholder and Executive Director of Reverse Corp (ASX: REF). Previously, he was a Managing Director of Ord Minnett and member of its Group Management Committee, a Principal of Elysium Capital Partners in London, a Managing Director (Equities) for Merrill Lynch in London after holding several positions in the Equities and Investment Banking divisions of SBC (now UBS) in London and SBC Dominguez Barry (now UBS) in Sydney.

Mr Lewin received a Bachelor of Commerce (First Class Honours) and a Bachelor of Laws (Honours) from University of Queensland. He was a visiting lecturer in business finance at the Queensland Institute of Technology. He received the Baillieu Research award in 1989.

Peter Gammell

Director
Close

Peter Gammell

Director

Peter Gammell is currently the Executive Chairman of Invictus Advisory Pty Ltd and Non-Executive Chairman of Octet Finance Pty Ltd. Prior to this role he was Chief Executive Officer of Seven Group Holdings and Deputy Chairman of Australian Capital Equity Pty Ltd (ACE), the Western Australian based holding company associated with Mr. Kerry Stokes. He was the Managing Director of ACE for 21 years which is now one of Australia’s largest private companies.

He has served as a Director of Seven Network Ltd, RM Williams Ltd, National Hire Ltd, Consolidated Media Holdings Ltd and was the Chairman of Coates Hire.

He led the creation of the Seven Media Group, a joint venture between Seven Network Limited and the private equity firm Kohlberg Kravis Roberts & Co. in 2006.

In June 2010 Mr Gammell was appointed the Chief Executive Officer of Seven Group Holdings Limited, a public company listed on the Australian Stock Exchange which was formed as a result of the merger of Seven Network Limited and WesTrac Holdings Pty Ltd.

He currently serves as a Director of Seven West Media Limited (formed in 2011 by the merger of West Australian Newspapers Holdings with Seven Media Group), is a Director of Thinksmart Ltd, a UK based consumer finance company which is listed on AIM in London, and in January 2018, joined the Board of Directors of OneVentures Pty Ltd.

During Peter’s career he has been instrumental in acquiring and building multi-billion dollar enterprises with in excess of $10 billion of mergers and acquisitions.

Mr Gammell is a member of the Institute of Chartered Accountants of Scotland and holds a Bachelor of Science degree from the University of Edinburgh.

Roger Massy-Greene

Director
Close

Roger Massy-Greene

Director

Roger is a director of OneVentures Pty Ltd, a technology venture capital firm, and is the principal shareholder and director of Eureka Capital Partners, a private investment concern. He is also a director of Illawarra Coke Company, an industrial land development concern.

Mr Massy-Greene previously served as the Chair of Ausgrid, Endeavour Energy and Essential Energy, having been appointed by the NSW government in 2012 to oversee reform of the NSW electricity distribution sector.

He previously co-founded the ASX 200 company Excel Coal Limited and its predecessor Resource Finance Corporation Ltd, and served as Chair of Excel Coal until its acquisition by Peabody Energy in 2006.

Mr Massy-Greene serves as Chair of Eureka Benevolent Foundation, a family foundation focused on overcoming socio-economic disadvantage.  He is the President of Cranbrook School and a director of The Hunger Project in the USA and Australia.

Jill Allen

Corporate Controller
Close

Jill Allen

Corporate Controller
  • Education

    CA / BEc

Jill started her career in corporate tax, ultimately having decided to transition into commercial accounting. She is essential for critical business functions and provides financial controlling as part of the F&O team.

She is an experienced and dedicated finance professional, also providing leadership and administrative support to keep the office running smoothly.

Jill is passionate about her 3 kids and enjoys keeping active and fit. She also likes cooking, art and hopes to one day start horse riding again… literally getting back on the horse.

Jill looks after the finance function for the OneVentures corporate entities, including financial accounting, taxation, management accounting and corporate secretarial.

She also supports Risk Management in the firm, looking after many internal controls, insurances for the business and provides assistance to the Risk Management Committee.

She oversees the outsourced IT support function and assists with HR administration (onboarding, offboarding, employment contracts).

Jill also brings her entrepreneurial spirit to OneVentures – she used to run an accounting business in a past life. During that time, she managed the successful merger with another practice to create a profitable, efficient business – and says she learnt a LOT along that journey!!

Matthew Lewin

Investment Analyst
Close

Matthew Lewin

Investment Analyst
  • Education

    BCom/BAdvStudies

Matt Lewin is an Investment Analyst on OneVentures’ Growth Fund V. Matt is energetic about supporting Australian founders and companies on their growth journey any way he can.

Prior to OneVentures, Matt has had experience in MA Financial Group, one of Australia’s leading investment banks covering technology. In addition to this, Matthew has investment experience at Tier 1 firms such as Perpetual, and VGI Partners – focusing on long-term horizon technology investing, ESG investing, and company analysis.

Outside of tech and investing, Matt’s passion lies firmly with history, philosophy, psychology, and economics. These topics are the intersection of human action – that is, exploring why we act, how we act, and why we act how we act. As an investor, it is crucial to understand the actions of oneself and others in a broad, multidisciplinary context. Matt is more than happy to bore you with ramblings on these topics if you ask.

Matt brings his experience across equity management and investment banking, as well an insatiable curiosity for innovation across all sectors.

At OneVentures, he helped source and supported the execution of three Fund V equity investments, in addition to ten venture credit investments.

Matt joined OneVentures in 2021 as an Investment Intern, supporting the investment teams across venture credit and equity in across the whole deal lifecycle: deal-sourcing, company analysis, and due-diligence. Since being promoted to Investment Analyst, he has continued to be an asset to the team in many ways – not only supporting the team, but also providing insight and shared learnings for the broader organisation.

Prior to joining OneVentures, Matt completed internships across investment banking (Moelis Australia) and equity management (VGI Partners, Perpetual), focusing on long-term horizon technology investing, ESG investing, and company analysis. Matt received a BCom/BAdvStudies, majoring in Finance and Banking from the University of Sydney – receiving the University Academic Merit Prize.

Joel Breuer

Investment Analyst Intern
Close

Joel Breuer

Investment Analyst Intern
  • Education

    Bachelor of Biomedical Engineering (Honours) / Bachelor of Commerce

Joel Breuer works across OneVentures’ Growth Equity, Credit and Healthcare investment teams. Joel is passionate about innovation and helping the next generation of founders secure funding to accelerate their growth.
Joel has been part of the OneVentures team since 2020, bringing with him startup and finance experience. Prior to OneVentures, Joel had operational roles at a PropTech and (now ASX listed) EdTech startup. Joel has had Capital Markets and M&A advisory experience at Barrenjoey, a disruptor in Australia’s Investment Banking sector.

Joel’s passion regarding innovation originated in HealthTech and Medical Devices, although has broadened across technology and software. In his Engineering Degree and work at OneVentues he enjoys diving into the first, second and third order benefits that innovation can provide to society and individual’s lives.

Joel is a self-confessed podcast addict, and can’t turn down a conversation regarding innovation, burgoening ideas and finance. Ask Joel for his recommended list (and make time in your schedule).

Outside of technology and finance, Joel is a regular practicer of yoga. Joel is additionally a passionate Ski Racer, who has previously raced as part of the USYD team.

Joel brings a drive and enthusium to the endless task of mapping Australia’s startup ecosystem. He brings strong financial skills and a desire to understand the granular workings of technology startups.

Joel has helped to source and delivery a number of opportunities through to OneVentures’ investment committee.

Since 2020 Joel has interned across OneVentures’ Growth Equity, Venture Credit and Healthcare teams. His work involves supporting the investment teams across the whole deal lifecycle: deal-sourcing, company analysis, and due-diligence.

Throughout his university degree, Joel has taken on a number of internships that have complemented his experience gained at OneVentures. This includes an internship in the General Industrials team at Investment Bank Barrenjoey, where he gained exposure to Healthcare and Technology IPOs and M&A transactions. Previously Joel worked at startups RentBetter (PropTech) and Cluey Education (EdTech). Joel is completing an Honours in Biomedical Engineering & Bachelor of Commerce (Finance) degree from the University of Sydney – he is a Dalyell and Sydney Scholar and has received the University Academic Merit Prize.

decor decor decor
decor decor decor decor decor